Operator fluency on fresh ground

Danaher Corporation (DHR) — this company's answers

The model's full reasoning — Q1 2017 call → NOWe need to determine if the transcript shows the dynamic described: a recently emerged positive element, probed by analysts, and management responds with unhesitating, granular operational command across at least two exchanges, conveying that the element's contribution is still early. First, identify the recently emerged positive element. The call mentions Pall and Cepheid as recent larger acquisitions. Cepheid is explicitly noted as "off to a great start" and achieved double-digit core revenue growth in the quarter. That seems like a recently emerged positive element. Also, the acquisition of AVT is announced, but that's not yet closed. Cepheid is the most likely candidate. Analysts probe Cepheid: In the Q&A, Ross Muken asks about Cepheid: "I just wanted to talk first maybe a bit about Cepheid. It looked like when I teased out the numbers, it was quite a very strong start to the year for them relative to what we were expecting at least. As you look at sort of the pipeline there and your channel opportunities and you start to understand what’s under the new products, the momentum that business could have, obviously you talked about 10% plus. It seems like it was much more of that in Q1. I guess, how are you thinking about variety of drivers and then what drove some of that outperformance or what appears to be in this quarter?" Tom Joyce responds with specifics: "We did have a very good quarter at Cepheid We’re extremely pleased with how that business has performed and how the team has come together and adapted to the Danaher environment, have utilized the tools of the Danaher Business System to drive improvements, not only in terms of the way they’re driving business commercially, but I think importantly, the way they are taking cost out of various areas of business and redeploying some of those savings back into investments for growth. And we’re starting to see the impact of that obviously across the top-line, where we talked about double-digit growth and meaningful margin improvements as well, now margin improvements that are in the double-digit range for sure. So, in terms of what’s driving that growth. It’s pretty well -- it’s pretty broad across the portfolio. Infectious disease, sexual health continues to perform quite well.

← Back to the full DHR analysis